Sanara MedTech Inc. to Participate in the TD Cowen 46th Annual Health Care Conference on March 3rd
MWN-AI** Summary
Sanara MedTech Inc. (Nasdaq: SMTI) is a pioneering medical technology company dedicated to the development and commercialization of innovative solutions aimed at enhancing clinical outcomes while simultaneously reducing healthcare costs in the surgical sector. The company is set to participate in the TD Cowen 46th Annual Health Care Conference, taking place from March 2-4, 2026, at the Boston Marriott Copley Place, where management will present to investors on March 3 at 9:10 a.m. Eastern Time. Investors can access the presentation materials and a live audio webcast on the company’s investor relations website.
Sanara specializes in providing advanced surgical products designed for use by healthcare professionals in hospitals and surgical facilities. Its extensive product portfolio includes notable offerings like CellerateRX® Surgical Activated Collagen® Powder, FORTIFY TRG® Tissue Repair Graft, and the BiFORM® Bioactive Moldable Matrix, among others. These products are largely focused on surgical tissue repair, catering primarily to the North American market.
The company aspires to solidify its position as a leader in delivering effective surgical solutions through a commitment to research, development, and adherence to stringent quality and regulatory standards. Sanara is actively exploring opportunities to expand its product range, ensuring that it meets the evolving needs of patients needing surgical care in the United States.
As part of its corporate strategy, Sanara is aware of the various risks associated with product development, regulatory approvals, and market competition. Consequently, the company remains vigilant in navigating these challenges to achieve its growth objectives and fulfill its mission to provide groundbreaking medical technologies. For further details, visit Sanara’s website at SanaraMedTech.com.
MWN-AI** Analysis
Sanara MedTech Inc. (Nasdaq: SMTI) is set to participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, a move illustrating the company’s intent to engage with investors and showcase its market potential. As a medical technology firm focused on improving surgical outcomes and reducing healthcare costs, Sanara's product portfolio, which includes innovative surgical solutions, positions it uniquely in the North American surgical tissue repair market.
Investors should closely monitor Sanara's presentation at the conference, particularly for insights into its strategic direction, developmental pipeline, and regulatory advancements. The company's ability to achieve favorable clinical outcomes while maintaining cost efficiency is critical; as healthcare expenditures continue to rise, demand for effective and affordable surgical technologies is expected to grow.
Moreover, Sanara's commitment to developing a comprehensive range of products—ranging from CellerateRX® to biocompatible grafts—could enhance its competitive edge. As such, investors should assess the market's reception of its flagship products, especially in light of increasing competition within the med-tech space.
While the forward-looking statements provided by the company highlight ambitious growth plans, it is essential to consider the inherent risks associated with the development of new products and regulatory approvals. Market fluctuations and economic conditions can significantly impact Sanara's operational success, thus careful scrutiny of their forthcoming presentations and subsequent performance reports is advised.
In conclusion, attending the healthcare conference may provide valuable insights for potential investors. Given Sanara MedTech’s focus on transformative medical technologies, along with an understanding of the related risks, there could be significant opportunities for growth if the company successfully navigates its strategic goals.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
FORT WORTH, TX, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that management will participate in the TD Cowen 46th Annual Health Care Conference, which is being held at the Boston Marriott Copley Place in Boston, MA from March 2 – 4, 2026. Management will deliver a presentation to investors on Tuesday, March 3 at approximately 9:10 a.m. Eastern Time.
The presentation materials for the conference will be posted to the Company’s investor relations website, https://ir.sanaramedtech.com/, prior to the presentation. A live audio webcast of the presentation will also be accessible under the “Events” section of the Company’s Investor Relations website at https://ir.sanaramedtech.com/. An archive of the webcast will be available for replay following the conference.
About Sanara MedTech Inc.
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The Company develops, markets and distributes surgical products for use by physicians and clinicians in hospitals. Each of the Company’s products and technologies are designed to achieve the goal of providing better clinical outcomes at a lower overall cost for patients. Sanara’s products are primarily sold in the North American surgical tissue repair market. Sanara markets and distributes CellerateRX® Surgical Activated Collagen® Powder, BIASURGE® Advanced Surgical Solution, FORTIFY TRG® Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix, as well as a portfolio of advanced biologic products including: ACTIGEN® Verified Inductive Bone Matrix, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix and TEXAGEN® Amniotic Membrane Allograft to the surgical market. The Company believes it can drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. The Company strives to be one of the most innovative and comprehensive providers of effective surgical solutions and is continually seeking to expand its offerings for patients requiring treatments in the United States. For more information, please visit SanaraMedTech.com.
Information about Forward-Looking Statements
The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” contemplates,” “continue,” “could,” “estimates,” “expects,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the Company’s business strategy and mission, the development of new products, the timing of commercialization of the Company’s products, and the regulatory approval process. These items involve risks, contingencies and uncertainties such as uncertainties associated with the development and process for obtaining regulatory approval for new products, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.
All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.
Investor Relations Contact:
Jack Powell or Mike Piccinino, CFA
ICR Healthcare
IR@sanaramedtech.com
FAQ**
How does Sanara MedTech Inc. (SMTI) plan to leverage its innovative surgical products to compete effectively in the North American surgical tissue repair market?
What specific timelines and milestones can investors expect regarding the commercialization of new products by Sanara MedTech Inc. (SMTI) post-conference?
How does Sanara MedTech Inc. (SMTI) intend to address potential regulatory challenges that may arise during the development of its new medical technologies?
What role do investor feedback and market demand play in shaping the product pipeline and future strategies at Sanara MedTech Inc. (SMTI)?
**MWN-AI FAQ is based on asking OpenAI questions about Sanara MedTech Inc. (NASDAQ: SMTI).
NASDAQ: SMTI
SMTI Trading
6.95% G/L:
$20.17 Last:
88,932 Volume:
$20 Open:
